We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

229 hedge funds and large institutions have $2.1B invested in Syndax Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 83 increasing their positions, 80 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more call options, than puts

Call options by funds: $30M | Put options by funds: $14.4M

35% more capital invested

Capital invested by funds: $1.56B → $2.1B (+$543M)

22% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 27

10% more funds holding in top 10

Funds holding in top 10: 10 → 11 (+1)

4% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 80

1% more funds holding

Funds holding: 227 → 229 (+2)

2.44% less ownership

Funds ownership: 117.38% → 114.94% (-2.4%)

Holders
229
Holders Change
+2
Holders Change %
+0.88%
% of All Funds
2.78%
Holding in Top 10
11
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+10%
% of All Funds
0.13%
New
33
Increased
83
Reduced
80
Closed
27
Calls
$30M
Puts
$14.4M
Net Calls
+$15.6M
Net Calls Change
+$3.08M

Top Buyers

1
HRCM
Hood River Capital Management
Florida
+$40.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$19M
3
Bank of America
Bank of America
North Carolina
+$17.7M
4
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$13.8M
5
State Street
State Street
Massachusetts
+$13M

Top Sellers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$51M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$30.4M
3
Millennium Management
Millennium Management
New York
-$17.3M
4
UBS Group
UBS Group
Switzerland
-$16.7M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$16.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
226
Clearstead Advisors
Ohio
$736 -$925 -53 -60%
BWA
227
Basecamp Wealth Advisors
Washington
$189 +$157 +9 New
QCG
228
Quadrant Capital Group
Ohio
$64 – – –
Adage Capital Partners
229
Adage Capital Partners
Massachusetts
– -$51M -3,311,963 Closed
ZP
230
Zimmer Partners
New York
– -$5.89M -383,100 Closed
IC
231
Ikarian Capital
Texas
– -$5.13M -333,733 Closed
BFM
232
Boothbay Fund Management
New York
– -$4.03M -261,933 Closed
Marshall Wace
233
Marshall Wace
United Kingdom
– -$3.6M -233,973 Closed
TCM
234
Tang Capital Management
California
– -$3.08M -200,000 Closed
Macquarie Group
235
Macquarie Group
Australia
– -$2.77M -180,000 Closed
KeyBank National Association
236
KeyBank National Association
Ohio
– -$2.31M -150,000 Closed
HF
237
HRT Financial
New York
– -$2.28M -148,139 Closed
Schroder Investment Management Group
238
Schroder Investment Management Group
United Kingdom
– -$1.92M -123,404 Closed
EAM
239
Exome Asset Management
New York
– -$1.81M -117,783 Closed
GAM
240
Gotham Asset Management
New York
– -$742K -48,246 Closed
SCM
241
Stonepine Capital Management
Oregon
– -$572K -37,200 Closed
PCM
242
Prelude Capital Management
New York
– -$504K -32,739 Closed
PF
243
Phoenix Financial
Israel
– -$489K -31,740 Closed
SRL
244
Scientech Research LLC
New Jersey
– -$475K -30,875 Closed
CCM
245
Cinctive Capital Management
New York
– -$468K -30,440 Closed
CCS
246
Concentric Capital Strategies
Connecticut
– -$338K -21,944 Closed
Allianz Asset Management
247
Allianz Asset Management
Germany
– -$234K -15,200 Closed
Commonwealth Equity Services
248
Commonwealth Equity Services
Massachusetts
– -$168K -10,906 Closed
Prudential Financial
249
Prudential Financial
New Jersey
– -$160K -10,395 Closed
SSG
250
Summit Securities Group
New York
– -$10.6K -688 Closed
7 8 9
10
11

SNDX Hedge Fund Activity: Q4 2025 in Review

229 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2025, worth a combined $2.1B — up 35% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new SNDX positions and 27 closed out — a net gain of 6 holders — while 83 added to existing stakes and 80 trimmed.

The largest buyer was Hood River Capital Management, opening a new position worth an estimated $40.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $51M sold.

  • 229 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2025, up from 227 in Q3 2025.
  • Funds reported $2.1B of Syndax Pharmaceuticals stock for Q4 2025, up 35% quarter-over-quarter.
  • 33 funds opened new Syndax Pharmaceuticals positions in Q4 2025 and 27 closed out, a net change of +6 holders.
  • The largest Syndax Pharmaceuticals buyer in Q4 2025 was Hood River Capital Management, an estimated $40.4M added.
  • The largest Syndax Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $51M sold.

Based on aggregated 13F filings for Q4 2025.